BTIG Research Begins Coverage on VYNE Therapeutics (NASDAQ:VYNE)

Equities researchers at BTIG Research initiated coverage on shares of VYNE Therapeutics (NASDAQ:VYNE) in a note issued to investors on Monday, Marketbeat reports. The firm set a “buy” rating and a $8.00 price target on the stock. BTIG Research’s price target would indicate a potential upside of 193.04% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and set a $5.75 price objective on shares of VYNE Therapeutics in a research note on Friday, November 8th.

VYNE Therapeutics Stock Up 0.4 %

Shares of NASDAQ:VYNE opened at $2.73 on Monday. The firm has a 50 day moving average of $2.31 and a 200 day moving average of $2.19. The company has a market capitalization of $40.27 million, a price-to-earnings ratio of -3.17 and a beta of 1.32. VYNE Therapeutics has a 52 week low of $1.57 and a 52 week high of $4.24.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Virtu Financial LLC purchased a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 16,199 shares of the company’s stock, valued at approximately $50,000. Virtu Financial LLC owned about 0.11% of VYNE Therapeutics at the end of the most recent quarter. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.